You do not knock off 8 percent, 5 1/8, because
earnings are a little off. This stock ran up on
misinformation and will continue to drop, probably right into
the $40's. It may bounce up and down for a while but
that is where this stock is heading. Get your money
out now, then decide if you want to buy back in. Take
it from someone who has been killed by optimism. You
are only sane when you are out of the stock. The
decision not to sell is the same as the decision to buy.
That concept is hard to get but it can save you a
bundle. Good luck.
Why were more Board members added? I don't know
what the general advantages would be to increasing
number, but there certainly is an advantage to this
company in adding members with these skills and
capabilities. More input on finance, R&D, and consumer products
can only strengthen the existing board.
think you're right on the money about BOL. Their move
to divest sunglasses to focus on pharmaceuticals is
an open challenge to both AGN and Alcon. Watch out
for them . . .
This Board is dead. Why was there a change in the
BD to 12 and will their be additional fallout. What
is happening with the lens market and is AGN holding
market share. Will B&L begin to make their move next
year after cleaning up the mergers with ChironVision
that seems to be taking time and with Storz. Can AGN
remain Nbr 2 to Alcon or will they fall to 3. Just
wanted to get things shaking again as the stock is
strong and maybe a great time to cash in before the next
dip. Any how just wanted to share some meanderings as
it was fun for awhile and kept everyone guessing. I
believe Mr Pyott the CEO even contributed
Price is moving right along--probably due to its
significant increased earnings per share. Where is this
coming from, do you think? Alphagan and BOTOX are doing
great, but I wonder how long this can be sustained.
What's going on with Zorac?
zin42, a curious
Regarding agn @$62, I don't have enough
information to know if its ahead of itself or not. With that
in mind, I would be reluctant to buy anymore right
As you know, it's frequently difficult to determine
exactly what is driving a stock price.
opinion, everything regresses to the historical mean
unless new factors are introduced. It's sort or like a
hitter in baseball who has averaged about.250 for ten
years then hits .500 for 3 months. Does that mean he is
now a .500 hitter for the future. Could be, but I
Best, the Deuce
board is really dead, eh?
I agree with your sage wisdom regarding buying
low and selling high (go figure?), however, you need
to do your homework before you jump to conclusions
on share price swings. To the best of my knowledge,
AGN's stock dropped 8% because of issues with their
botulinum toxin plant. My guess is since Botox plays such a
big part of AGNs profits today and tomorrow investors
got a bit concerned. 24 hours after the LA Times
publishes the article all is well and the price is back up.
I personally applaud AGN's ability to move quickly,
reconcile the issue, and communicate to the investment
community that all is well.
In the old days AGN
might still be trying to decide what to do with the
Those familiar with FDA responses will know that
they get immediate attention and extremely fast turn
around times. There seems to be a greatly improved
credibility of AGN by all--the street, FDA, and a little by
the local press (good grief, could this be
true!!)instilled by the NEW management.
Just a comment
about the 'old and new'AGN. In the past, they seemed to
know what they wanted to do, but didn't know exactly
how to do it (or couldn't agree on the plan) Thus it
never got done--all talk. Now, Pyott seems to know
exactly what to do, how to do it--make a plan, get it
approved, communicate it, AND implement it. Let's face it,
he is good and what AGN always needed. I like him
(and also the stock at 60).
This is my first post here, but I have been
reading with interest for a while. The reason for the
weakness in Allergan today is probably due to an afternoon
story on Bloomberg news. Apparently the FDA issued some
sort of warning letter as a result of a July
inspection of an AGN plant in Ireland which manufactures
Botox. As most of you know, Botox has been one of AGN's
fastest growing products, and it now accounts for
approximately 10% of sales.
From what I've been able to
find out so far, the story is overblown, and will not
affect sales or production of Botox. The FDA is simply
seeking clarification of the company's procedures. There
are no fines involved. The company will probably
discuss this when they release earnings tomorrow
P.S. I am not an Allergan employee, past nor present.
I am, however, a shareholder who has benefited from
the improving outlook.
I think you're correct. There was an article in
the L.A. Times this am. Agn seems to be bouncing back
nicely on reasonably heavy volume this morning. Agn,
like many other equities, is unfortunately subject to
the "chicken-little" syndrome of a volitile market
Speaking of Botox, does anyone know of any competitiors on
the horizon? I know the product is quite difficult to
and where do you get your info...bet you are
wrong...agn will beat estimates,but won't surprise big...the
reason this stock is up and down like a yo-yo is due to
all the momentum players in here...this stock will
continue to trade in the mid 50 range until bad news
hits...at least that is what i think...heck,no one really